ArticleSubstance abuse : research and treatment2020
The Anabolic Androgenic Steroid Treatment Gap: A National Study of Substance Use Disorder Treatment.
Article in Substance abuse : research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 40 citations in OpenAlex.
- Anabolic-androgenic steroid use disorder: case for recognition as a substance use disorder with specific diagnostic criteria.The British journal of psychiatry : the journal of mental science · 2026Review
- Muscle Dysmorphia, Obsessive-Compulsive Traits, and Anabolic Steroid Use: A Systematic Review and Meta-Analysis.Behavioral sciences (Basel, Switzerland) · 2025Review
- Psychological traits associated with anabolic androgenic steroid use and dependence: an exploratory cross-sectional study among female athletes.BMC women's health · 2025Article
- Predicting Anabolic Androgenic Steroid Doping among Specialized Health Care Patients with Elastic Net Regression Reveals Potential Laboratory Variables for "Patient Biological Passport".Sports medicine - open · 2025Article
- Impaired vascular function among young users of anabolic-androgenic steroids.Scientific reports · 2024Article
- Supraphysiological testosterone levels from anabolic steroid use and reduced sensitivity to negative facial expressions in men.Psychopharmacology · 2024Article
- Clustering psychopathology in male anabolic-androgenic steroid users and nonusing weightlifters.Brain and behavior · 2023Article
- Investigating anabolic-androgenic steroid dependence and muscle dysmorphia with network analysis among male weightlifters.BMC psychiatry · 2023Article
- Female doping: observations from a data lake study in the Hospital District of Helsinki and Uusimaa, Finland.BMC women's health · 2023Article
- Anabolic-Androgenic Steroid Use: Patterns of Use among a National Sample of Canadian Adolescents and Young Adults.Performance enhancement & health · 2023Article
- ADHD symptoms and use of anabolic androgenic steroids among male weightlifters.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnabolic androgenic steroid (AAS) use is associated with serious mental and physical health problems. Evidence indicates that AAS use among people who use psychoactive substances is higher than in the general population. This study aims to estimate lifetime AAS use among patients in substance use disorder (SUD) treatment, compare characteristics of AAS and non-AAS users and identify whether AAS use was addressed during treatment.
methodsThis cross-sectional survey included 563 (142 women, 24.2%) patients in 38 SUD treatment facilities in Norway. Respondents reported on AAS and substance use, and treatment experiences.
resultsLifetime AAS use was reported by 156 (28.3%) SUD patients, thereof 35.6% of the men and 8.0% of the women. Lifetime AAS use was highest among men with stimulants (55.8%) as preferred substance, and lowest among men who preferred alcohol (14.6%). Initiation of AAS use due to getting thinner following substance use was reported by 44.5% of the AAS using men. AAS users reported more severe substance use than non-AAS users. More than half (58%) of all patients had not been asked about AAS use, and 42.4% of those who were asked, experienced that treatment providers lacked expertise about AAS.
conclusionLifetime AAS use in this sample of SUD patients is common practice and comprise an underrecognized problem in SUD treatment. Given the deleterious implications to the individual and society that concomitant use of AAS may cause, it would be essential to raise the awareness about AAS use among SUD patients, and the level of competence among health professionals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.